Competitive Grants Program
Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP. The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.
Sign up to receive all grant announcements, including Request for Proposal (RFP) postings.
Sign Up for Alerts Details-
Title Grant Type Focus Area Country Application Due Date Real World Evidence on the Impact of Early and Appropriate Use of Aztreonam-Avibactam (ATM-AVI)Release Date:Research Inflammation & Immunology Brazil, Chile, India, Italy, South Africa, Spain, United Kingdom Guideline Concordant Care and New Data for Patients with MIBC through la/mUCEducation Oncology USA Clinical Research Studies of Atirmociclib in HR+/HER2- and/or HER2+ Breast CancerRelease Date:Research Oncology Australia, Brazil, Canada, China, France, Germany, Italy, Japan, Korea, Mexico, Spain, Taiwan, USA, United Kingdom Quality Improvement Interventions to Enhance the Care of Patients Infected by MBL-CRE or S. maltophiliaRelease Date:Quality Improvement Inflammation & Immunology Australia, Chile, India, Italy, Spain, United Kingdom Advancing Real-World Evidence in Idiopathic Inflammatory Myopathies Through a German Disease RegistryRelease Date:Research Inflammation & Immunology Germany Real-World Evidence on Clinical Outcomes with ATM-AVI in Adult Patients with Stenotrophomonas maltophilia InfectionsRelease Date:Research Inflammation & Immunology China Real-World Evidence on Clinical Outcomes with Aztreonam-Avibactam (ATM-AVI) in Adult Patients with Limited Treatment OptionsRelease Date:Research Inflammation & Immunology China Tissue Penetration and Correlation with Clinical Outcomes of ATM-AVI in Adult Patients with Limited Treatment OptionsRelease Date:Research Inflammation & Immunology China Advancing Multidisciplinary Care in HemophiliaRelease Date:Quality Improvement Rare Disease China BCMA BsAb Educational Initiatives in 2L+ Relapsed/Refractory Multiple MyelomaRelease Date:Education Oncology USA -
Title Grant Type Focus Area Country Application Due Date Optimizing Androgen Deprivation Therapy (ADT) in Advanced Prostate CancerEducation Oncology USA Optimizing Biomarker-Directed Therapy in Metastatic Colorectal CancerRelease Date:Partner: The National Comprehensive Cancer Network®, Fight Colorectal CancerQuality Improvement Oncology USA Addressing the Needs of Patients with Mental Health Issues and Dermatological Inflammatory ConditionsRelease Date:Quality Improvement Inflammation & Immunology Canada Quality Improvement Grants to Improve Identification and Management of Patients with ATTR-CMRelease Date:Quality Improvement Rare Disease Canada Transthyretin Amyloid Cardiomyopathy (ATTR-CM) ResearchRelease Date:Research Rare Disease USA Improving Treatment Environment and Survivorship for Multiple MyelomaRelease Date:Education Oncology Japan Improving Treatment Environment and Survivorship for LeukemiaRelease Date:Education Oncology Japan Advances in the Management of Ulcerative Colitis (UC) (Europe, Canada, Japan, South Korea, Australia, New Zealand, Israel)Release Date:Education Inflammation & Immunology All Increasing Awareness and Understanding of Transthyretin Cardiomyopathy (ATTR-CM)Release Date:Education Rare Disease USA Shared Decision-Making (SDM) for Patient Quality of Life in Cancer Treatment and Improving Access to BiologicsRelease Date:Education Oncology Japan Improvement of Treatment Environment of Immuno-Oncology Therapy for Urothelial CancerRelease Date:Quality Improvement Oncology Japan Optimizing the management of mBC HER2-patients / OncologyRelease Date:Quality Improvement Oncology Italy